PHARMA & BIOTECH
Diseases linked to aging are opening up new areas of investigation for academic researchers, as well as for manufacturers, who find on the Côte d’Azur, given the demographic pyramid and the high concentration of practitioners and researchers, an ideal location for combining basic research, clinical trials and experiments.
The Côte d’Azur thus enables local stakeholders to trial their technology on a population representative of France as a whole and Europe in ten years’ time.
The Côte d’Azur boasts a growing number of specialist areas in various diseases:
Infectiology/Oncology/Microbiology/Neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease)/Dermatology/Cell therapy/Diabetes
Innovation in life sciences is supported by public research divided into centres of excellence around the Institute of Molecular and Cellular Pharmacology (IPMC), the Mediterranean Centre for Molecular Medicine (C3M), the Valrose Institute of Biology (IBV), the Research Institute on Cancer and Aging (IRCAN), the Antoine Lacassagne Centre, the Nice Chemistry Institute and the French National Institute for Research in Computer Science and Automation (INRIA) (Therachon, spin off from the university acquired in 2019 by Pfizer for 340M$).
/ Presence of the largest competitiveness hub in France and ranked among the best in the Eurobiomed cluster: 172 R&D projects representing 718 million euros investment and 700 direct jobs.
/ 1 faculty of medicine with 5 mixed clinical resarch units
/Cardio-respiratory physiology: CARRES
- Immuno-transplantation: INNOVANT
- Movement: IULS
- Pain: PIN
- Imaging: URRIS